| Wednesday | ||||
Biotechnology Analyst… Biotechnology Analyst Goldstein, along with Drs. Velcheti and Oberstein discuss targeted therapies in lung and GI cancer, (ERAS, IMRX, VSTM, MRK, INCY, EFTR, LPTX, RCUS, CRVS) as well as emerging trends and themes to be covered at the upcoming ASCO 2023 Annual Meeting on an Analyst/Industry conference call to be held on May 24 at 10 am. | ||||
Biotechnology Analyst… Biotechnology Analyst Goldstein, along with Drs. Velcheti and Oberstein discuss targeted therapies in lung and GI cancer, (ERAS, IMRX, VSTM, MRK, INCY, EFTR, LPTX, RCUS, CRVS) as well as emerging trends and themes to be covered at the upcoming ASCO 2023 Annual Meeting on an Analyst/Industry conference call to be held on May 24 at 10 am. | ||||
| Over a week ago | ||||
Biotechnology Analyst… Biotechnology Analyst Goldstein, along with Drs. Velcheti and Oberstein discuss targeted therapies in lung and GI cancer, (ERAS, IMRX, VSTM, MRK, INCY, EFTR, LPTX, RCUS, CRVS) as well as emerging trends and themes to be covered at the upcoming ASCO 2023 Annual Meeting on an Analyst/Industry conference call to be held on May 24 at 10 am. | ||||
| Over a month ago | ||||
Mizuho analyst Mara… Mizuho analyst Mara Goldstein upgraded Immuneering to Buy from Neutral with a price target of $20, up from $10, following a presentation of IMM-1-104 data. The data presented shows IMM-1-104's PK profile is consistent with what was predicted preclinically, which provides "initial validation," the analyst tells investors in a research note. The data, from an initial four patients, showed a profile consistent with preclinical work with a tolerable safety profile thus far, says the firm, As a result, it increased its probability of success for IMM-1-104. | ||||
Morgan Stanley upgraded… Morgan Stanley upgraded Immuneering to Equal Weight from Underweight with a price target of $14, up from $5. The company accelerated timelines for its Phase 1 study with a recommended Phase 2 dose expected by early 2024, the analyst tells investors in a research note. The firm cites "encouraging" initial results and greater clarity on the timing of upcoming catalysts for the upgrade. | ||||
Chardan analyst Geulah… Chardan analyst Geulah Livshits raised the firm's price target on Immuneering to $22 from $18 and keeps a Buy rating on the shares. The company presented initial human data from the Phase I/IIa trial of lead MEK inhibitor IMM-1-104 demonstrating a two hour half-life consistent with preclinical modeling and transient~90% MAPK pathway suppression as measured by pERK, the analyst tells investors in a research note. The analyst says the data support translatability for IMM-1-104. | ||||
Immuneering… Immuneering "announced the pricing of its underwritten offering of 2,727,273 shares of its Class A common stock at an offering price of $11.00 per share. The gross proceeds from the offering are expected be $30 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Immuneering. All shares in the offering will be offered by Immuneering. Jefferies, TD Cowen and Guggenheim Securities are acting as the joint book-running managers for the offering." | ||||
Immuneering announced… Immuneering announced positive initial pharmacokinetic, PK, pharmacodynamic, PD, and safety data from the Phase 1 trial of IMM-1-104, which are being shared today in a poster presentation titled "Humanized 3D tumor models that are mutationally aligned with AACR GENIE patients predict IMM-1-104 activity in RAS-addicted tumors" at the American Association for Cancer Research, AACR, annual meeting. "We are very pleased to share initial PK, PD and safety data from our Phase 1 trial of IMM-1-104 in patients with advanced RAS mutant solid tumors, ahead of schedule," said Ben Zeskind, Ph.D., MBA, Co-founder, and Chief Executive Officer of Immuneering. "We believe these data from the first patients dosed in our study demonstrate the PK, PD and safety profile necessary for deep cyclic inhibition - the proprietary and novel mechanism through which our therapies are designed to selectively impact cancer cells to a greater extent than healthy cells, regardless of the specific RAS mutation driving the tumor. The data show that we were able to reach significant levels of PK Cmax with the aim of breaking tumor addiction to the MAPK pathway, then rapidly clearing out drug with IMM-1-104's short half-life. These results position us to accelerate the dose escalation portion of our study, reaching potentially therapeutic levels of IMM-1-104 earlier than previously planned." The Phase 1/2a clinical trial is an open-label study designed to evaluate the safety, tolerability, PK and preliminary efficacy of IMM-1-104 in patients with advanced RAS mutant solid tumors. The Phase 1 portion of the study, which is being conducted at five clinical sites in the United States, is evaluating IMM-1-104 following a Bayesian mTPI-2 escalation design, which includes a dose escalation phase and dose evaluation phase to establish an optimized RP2D candidate. Following selection of the RP2D candidate, the Company expects to conduct a Phase 2a dose expansion phase to assess the safety and efficacy of IMM-1-104 at the RP2D in RAS mutated pancreatic, melanoma, lung and colorectal cancers. | ||||
Mizuho analyst Mara… Mizuho analyst Mara Goldstein initiated coverage of Immuneering with a Neutral rating and $10 price target. The shares have doubled year-to-date following news that interim Phase I dose escalation IMM-1-104 data will be available in Q2, but clinical evidence of feasibility is now needed to expand the valuation further, the analyst tells investors in a research note. | ||||
